Small Businesses

Pfizer, Moderna CEOs predict a return to “normal life” in a year

  • 2 min Read
  • September 28, 2021

Author

Escalon

Table of Contents

Pfizer CEO and Chairman Albert Bourla said he anticipates a global return to regular pre-pandemic life by the end of 2022.  “Within a year I think we will be able to come back to normal life,” Bourla stated in a recent interview on ABC News

Bourla added that this does not mean variants of the coronavirus will cease to exist or that COVID-19 vaccines will become unnecessary. The most likely scenario is that “normalcy” will include the emergence of new variants of the virus. That means annual revaccinations as booster shots are almost certainly going to be a part of the landscape. 

But for a clearer picture, Bourla advises taking a wait-and-see approach based on newer data as it becomes available.

Bourla’s sentiment echoed by Moderna CEO

Stephane Bancel, the CEO of Moderna, also expects normal life will resume by next year, assuming COVID-19 vaccine production increases to ensure a sufficient global supply.

“If you look at the industry-wide expansion of production capacities over the past six months, enough doses should be available by the middle of next year so that everyone on this earth can be vaccinated,” Bancel said in an interview, Reuters reported. “Boosters should also be possible to the extent required.”

Like Bourla, Bancel emphasized that annual coronavirus vaccine booster shots will also “undoubtedly” be required after the pandemic is contained.

CDC approves, WHO opposes

Bourla’s and Bancel’s comments followed the U.S. Food and Drug Administration’s decision to recommend the third dose of COVID-19 booster shots of Pfizer’s vaccine for certain populations.

On Sept. 24, the Centers for Disease Control and Prevention authorized the distribution of the Pfizer-BioNTech COVID-19 Vaccine to older Americans and adults with underlying medical conditions. And in an unusual decision, CDC Director Dr. Rochelle Walensky overruled an advisory panel and approved the boosters for U.S workers in high-risk occupational and institutional settings. 

Meanwhile, citing the importance of equitable vaccine distribution, the World Health Organization continues to strongly oppose the widespread rollout of booster shots.

Talk to our team today to learn how Escalon can help take your company to the next level.

  • Expertise you can trust

    Our team is made up of seasoned professionals who bring years of industry experience to the table. You gain a trusted advisor who understands your business inside out.

  • Quality and consistency

    Say goodbye to the hassles of hiring, training and managing in-house finance teams. You will never have to worry about unexpected leave of absence or retraining new employees.

  • Scalability and Flexibility

    Whether you’re a small business or a global powerhouse, our solutions scale with your needs. We eliminate inefficiencies, reduce costs and help you focus on growing your business.

Contact Us Today!

Tap into the latest insights from experts in your industry

Life Sciences

Transfer Pricing Considerations for Life Sciences Companies Expanding Globally  

Global expansion is one of the most exciting milestones a life sciences company can hit. New markets, new clinical partnerships,...

Accounting & Finance

The Role of Accounting Software in Simplifying Audit Prep  

If you have ever spent the weeks before an audit digging through spreadsheets, chasing down receipts, or reconciling accounts that should have...

Taxes

The SMB Owner’s Audit Preparation Timeline: 90 Days Out 

Three months before your audit starts is when you should begin serious preparation, not three days. Yet many business owners...

Taxes

The Cost of Waiting: Why Proactive Voluntary Disclosure Agreement (“VDA”) Filing Almost Always Beats an Audit 

Unaddressed, historical state tax exposure is often an outgrowth of being focused on building a company and not properly keeping track of  an expanding state and local tax footprint. The exposure accumulated as the...

Taxes

R&D Tax Credits for Non-Tech Companies: Are You Missing Out? 

When most business owners hear "R&D tax credit," they immediately think of software companies and biotech firms. This narrow perception costs non-tech businesses billions...

Taxes

5 Business Triggers That Should Prompt an Immediate Nexus Review 

There is a persistent myth in the world of state and local tax compliance that a nexus review is something...

Accounting & Finance

The SaaS Rule of 40: What It Means and How to Achieve It 

If you're running a SaaS business and talking to investors, you've probably heard someone mention the Rule of 40. This simple metric has become a...

Accounting & Finance

Common Audit Findings in SMBs and How to Avoid Them 

Nobody enjoys finding out that their financial audit uncovered significant deficiencies. Yet according to data from the Center for Audit...

People Management & HR

The True Cost of Employee Turnover: How to Calculate and Reduce It 

Employee turnover represents one of the most significant yet often underestimated costs facing American businesses today. While most business owners recognize that...